Rheumatoid Arthritis (RA) is a complex, chronic, systemic autoimmune inflammatory disease primarily characterized by synovial hyperplasia, destruction of articular cartilage and bone tissue, and remodeling. RA affects approximately 1% of the global population, significantly reducing patients' quality of life. The development of new therapies relies on preclinical models capable of accurately mimicking human disease characteristics. Prisys Biotech's non-human primate (NHP)-based RA model provides a precise and reliable research tool, injecting new momentum into the exploration of RA treatments.
Why Choose a Non-Human Primate Model for RA Research?
Current RA research frequently utilizes rodent models; however, these models exhibit significant differences from humans in terms of immune system complexity and joint structure, limiting the clinical translatability of research findings. Non-human primates (such as cynomolgus monkeys used by Prisys Biotech) share a high degree of similarity with humans in their immune systems and joint structures, making them ideal models for studying RA pathogenesis, disease progression, and therapeutic responses.
Key Advantages of Prisys Biotech's RA Model
High Fidelity to Human Disease Characteristics:
Prisys Biotech's RA model is based on collagen-induced arthritis (CIA), which authentically replicates the key pathological features of RA, including synovial inflammation, articular cartilage and bone destruction, and joint swelling and dysfunction.
Comprehensive Disease Assessment System:
We have established a scientific and multi-dimensional assessment system, including:
- Detailed Joint Examination: Rigorous assessment following standardized protocols across all 64 joints of each animal, including MCP, PIP, DIP, carpal/tarsal, and knee/elbow joints.
- Dynamic Scoring Monitoring: Regular recording of arthritis scores and the onset and progression of the disease.
- Imaging Evaluation: Direct visualization of bone density loss and joint deformation through X-ray or CT imaging.
- Biomarker Analysis: Detection of RA-related biomarkers in serum and synovial fluid, such as CRP, ALP, anti-type II collagen antibodies, IL-6, TNF-α, and GM-CSF, providing crucial evidence for disease diagnosis and efficacy evaluation.
- Histopathological Analysis: Examination of joint tissue staining to investigate disease pathology mechanisms.
- Body Weight Monitoring: Recording changes in animal body weight to assess the systemic impact of the disease.
Data-Driven Model Validation:
Systematic analysis of incidence rates, arthritis scores, imaging data, and biomarker data validates the stability and reliability of the model (correlation analysis between CRP and arthritis probability/severity).
Precise Evaluation of Therapeutic Interventions:
Prisys Biotech's NHP RA model is suitable for evaluating the efficacy of traditional drugs (such as methotrexate and dexamethasone) and novel biologics, supporting both confirmatory and exploratory endpoint analyses to meet diverse research needs.
Leading Technology and Expertise:
Prisys Biotech is an industry leader, being among the first teams to establish an industrial-grade cynomolgus monkey CIA model. Through continuous optimization of model establishment and evaluation methods, we achieve high incidence rates (90-100%) and excellent reproducibility.
AI-Powered 3D Behavioral Analysis and Treadmill Technology: Novel Tools for RA Assessment
Recognizing the clinical need to analyze improvements in motor function following treatment interventions beyond immune modulation, Prisys Biotech has pioneered the establishment of a proprietary AI-3D cynomolgus monkey behavioral quantification analysis system. This system can be used to establish behavioral atlases of RA in monkeys and to analyze behavioral improvements after drug intervention, enhancing the translatability of preclinical data and enriching the dimensions of efficacy assessment.
AI 3D Behavioral Analysis System
The NHP Behavior Atlas system utilizes AI algorithms and multi-view three-dimensional tracking to achieve automated and refined analysis of animal behavior:
- Automatic Identification: Rapidly captures skeletal structures and behavioral sequences without physical markers or manual intervention.
- Behavioral Spectrum Analysis: Covers 14 common behaviors with the potential for expanded recognition, precisely recording gait and movement changes.
- Dynamic Monitoring: Sensitively detects movement trajectories, generating kinetic data such as knee joint angles, providing crucial evidence for functional disease assessment.
- Treadmill Dynamic Assessment Technology: Real-time capture of movement trajectories and gait characteristics quantifies motor function changes caused by RA, particularly suitable for gait analysis and weight-bearing experiments.
Prisys Biotech: Your Reliable Partner in RA Research
Prisys Biotech not only provides high-quality RA models but also is committed to offering comprehensive technical support and customized services to our clients, including:
- Experienced Research Team: Extensive experience in NHP model construction and disease research, providing expert consultation and technical support to clients.
- Standardized Experimental Operating Procedures: Strict adherence to international standards ensures data reliability and reproducibility.
- Customized Research Plans: Designing personalized experimental plans based on specific research needs to ensure successful project implementation.
Conclusion
Breakthroughs in rheumatoid arthritis research depend on scientifically rigorous preclinical models. Prisys Biotech's NHP RA model, with its high fidelity to human disease characteristics, comprehensive assessment system, and extensive technical expertise, provides significant support for RA drug development and translational medicine. We look forward to working with you to advance RA treatment research and bring more hope and well-being to patients.
Contact Us:
To learn more about Prisys Biotech's RA model, please visit our website at www.prisysbiotech.com or contact our business development team at bd@prisysbiotech.com.
About Prisys Biotech
Prisys Biotechnology Co., Ltd. specializing in preclinical and quasi-clinical evaluation of new drugs and new drug technology development, and has obtained full AAALAC accreditation.
Prisys Biotech is dedicated to becoming a leader in large animal pharmacology and efficacy research, focusing on preclinical and quasi-clinical evaluation of new drugs and the development of new drug technologies. We provide services including disease models based on non-human primates (cynomolgus monkeys) and other experimental animals, pharmacology and efficacy studies, safety evaluation, biomarker research, and mechanism proof-of-concept studies. Prisys Biotech has established a translational medicine center that meets pharmaceutical industry standards and has established long-term collaborations with numerous top domestic and international pharmaceutical companies, biotechnology companies, and academic research institutions.
